TLSA
Tiziana Life Sciences Ltd (TLSA)
Healthcare • NASDAQ • $1.12-3.45%
- Symbol
- TLSA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.12
- Daily Change
- -3.45%
- Market Cap
- $147.62M
- Trailing P/E
- N/A
- Forward P/E
- -5.81
- 52W High
- $2.60
- 52W Low
- $1.04
- Analyst Target
- $8.87
- Dividend Yield
- N/A
- Beta
- 0.42
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Company websiteResearch TLSA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.